Key result
The Cardioband system is a catheter-delivered annular reduction therapy that safely reduces functional mitral and tricuspid regurgitation, with ongoing randomized trials evaluating its long-term clinical benefits.
Why the study?
Does the Cardioband transcatheter annular reduction system improve clinical outcomes and reduce regurgitation in patients with functional mitral or tricuspid regurgitation?
Does the Cardioband transcatheter annular reduction system improve clinical outcomes and reduce regurgitation in patients with functional mitral or tricuspid regurgitation?
The Cardioband transcatheter annular reduction system is a promising, minimally invasive approach that safely reduces functional mitral and tricuspid regurgitation and improves symptoms, with ongoing pivotal trials to establish its clinical efficacy compared to medical therapy.
Cardioband enables percutaneous annular reduction for MR/TR; extends surgical principles to transcatheter repair pending randomized outcomes.
Surgical implantation of a complete or incomplete ring to reduce the mitral valve annulus and improve leaflet coaptation is the foundation of valve repair for degenerative and functional mitral and tricuspid regurgitation. The Cardioband system (Edwards Lifesciences, Irvine, CA, USA) is a catheter-delivered annular reduction system that mimics the surgical approach. Sequential anchors are used to secure the Cardioband implant from trigone to trigone. The Cardioband implant is contracted under transesophageal guidance until valvular regurgitation is reduced. In the initial clinical experience, the Cardioband system was safely deployed in patients with clinically significant functional mitral regurgitation (MR) and yielded durable MR reduction, improved quality of life, and improved exercise capacity. The early and still-evolving Cardioband experience for tricuspid regurgitation is also promising. The ongoing pivotal ACTIVE Trial is designed to demonstrate the superiority of the Cardioband system to guideline-directed medical therapy in patients with clinically significant functional MR (FMR) using a composite endpoint of mortality, heart failure (HF) hospitalization, quality of life, and exercise capacity.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2018) conducted a review in Functional mitral and tricuspid regurgitation. Cardioband transcatheter annular reduction system was evaluated. The Cardioband system is a catheter-delivered annular reduction therapy that safely reduces functional mitral and tricuspid regurgitation, with ongoing randomized trials evaluating its long-term clinical benefits.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: